The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease

被引:32
作者
Campbell, S
George, DK
Robb, SD
Spooner, R
McDonagh, TA
Dargie, HJ
Mills, PR
机构
[1] Gartnavel Royal Hosp, Dept Gastroenterol, Glasgow G12 0YN, Lanark, Scotland
[2] Torbay Hosp, Dept Gastroenterol, Torquay, Devon, England
[3] Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland
[4] Gartnavel Royal Hosp, Dept Biochem, Glasgow, Lanark, Scotland
[5] Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland
关键词
D O I
10.1136/heart.89.9.1023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Excess iron stores have been postulated to enhance the risk of ischaemic heart disease. This study aims to determine whether the two major mutations of the haemochromatosis (HFE) gene (C282Y and H63D) are associated with ischaemic heart disease (IHD) or myocardial infarction (MI). Design: Cross sectional case-control study. Setting: The geographical area studied by the MONICA (monitoring trends and determinants in cardiovascular disease) heart attack register for North Glasgow in Scotland, UK. Patients: 1009 control subjects chosen at random from general practitioner registers were studied. Additionally, 924 subjects who had survived a first MI sustained between 1985 and 1992 were identified from the MONICA register. Main outcome measures: C282Y and H63D mutations, previous MI, and presence or absence of IHD. Results: Mutant gene prevalences in the whole control population were as follows: C282Y: homozygote 0.9%, heterozygote 17.7%; H63D: homozygote 2.1%, heterozygote 25.5%; and compound heterozygote: 2.4%. Analysis by chi(2) test and logistic regression analysis did not identify any significant difference in genotype prevalence between normal control, IHD control, and MI survivor groups. Conclusions: The C282Y homozygote and heterozygote prevalences are among the highest reported worldwide. No association between IHD or MI and HFE genotype was identified. However, these results need to be interpreted in the light of the cross sectional case-control nature of the study.
引用
收藏
页码:1023 / 1026
页数:4
相关论文
共 24 条
[1]   Haemochromatosis gene mutations and risk of coronary artery disease [J].
Battiloro, E ;
Ombres, D ;
Pascale, E ;
D'Ambrosio, E ;
Verna, R ;
Arca, M .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2000, 8 (05) :389-392
[2]   The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic [J].
Beutler, E ;
Felitti, V ;
Gelbart, T ;
Ho, N .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (05) :329-337
[3]  
BLAND JM, 1995, INTRO MED STAT, V8, P125
[4]   Genetic hemochromatosis, a Celtic disease: Is it now time for population screening? [J].
Byrnes, V ;
Ryan, E ;
Barrett, S ;
Kenny, P ;
Mayne, P ;
Crowe, J .
GENETIC TESTING, 2001, 5 (02) :127-130
[5]   HFE gene mutations in coronary atherothrombotic disease [J].
Calado, RT ;
Franco, RF ;
Pazin, A ;
Simöes, MV ;
Marin-Neto, JA ;
Zago, MA .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2000, 33 (03) :301-306
[6]   Coronary heart disease and iron status - Meta-analyses of prospective studies [J].
Danesh, J ;
Appleby, P .
CIRCULATION, 1999, 99 (07) :852-854
[7]   A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis [J].
Feder, JN ;
Gnirke, A ;
Thomas, W ;
Tsuchihashi, Z ;
Ruddy, DA ;
Basava, A ;
Dormishian, F ;
Domingo, R ;
Ellis, MC ;
Fullan, A ;
Hinton, LM ;
Jones, NL ;
Kimmel, BE ;
Kronmal, GS ;
Lauer, P ;
Lee, VK ;
Loeb, DB ;
Mapa, FA ;
McClelland, E ;
Meyer, NC ;
Mintier, GA ;
Moeller, N ;
Moore, T ;
Morikang, E ;
Prass, CE ;
Quintana, L ;
Starnes, SM ;
Schatzman, RC ;
Brunke, KJ ;
Drayna, DT ;
Risch, NJ ;
Bacon, BR ;
Wolff, RK .
NATURE GENETICS, 1996, 13 (04) :399-408
[8]  
Franco RF, 1998, BRIT J HAEMATOL, V102, P1172
[9]  
HARDY GH, 1908, SCIENCE, V28, P41
[10]   Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases [J].
Hetet, G ;
Elbaz, A ;
Gariepy, J ;
Nicaud, V ;
Arveiler, D ;
Morrison, C ;
Kee, F ;
Evans, A ;
Simon, A ;
Amarenco, P ;
Cambien, F ;
Grandchamp, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2001, 31 (05) :382-388